ライフサイエンスコーパス: bictegravir

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 (1:1) to receive oral fixed-dose combination bictegravir 50 mg, emtricitabine 200 mg, and tenofovir a

2 block size of four), to receive coformulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir a

3 Bictegravir, a novel, once-daily, unboosted INSTI, showe

4 Administration of bictegravir, a novel, potent, once-daily INSTI designed

5 study comparing initial HIV-1 treatment with bictegravir-a novel INSTI with a high in-vitro barrier t

6 e aimed to assess the efficacy and safety of bictegravir coformulated with emtricitabine and tenofovi

7 ned 631 participants to receive coformulated bictegravir, emtricitabine, and tenofovir alafenamide (n

8 INTERPRETATION: At 48 weeks, coformulated bictegravir, emtricitabine, and tenofovir alafenamide ac

9 Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide do

10 ere randomly assigned to treatment (327 with bictegravir, emtricitabine, and tenofovir alafenamide fi

11 d in 92.4% of patients (n=290 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide gr

12 h occurred less frequently in patients given bictegravir, emtricitabine, and tenofovir alafenamide th

13 related to study drug were less common with bictegravir, emtricitabine, and tenofovir alafenamide th

14 6; p=0.78), demonstrating non-inferiority of bictegravir, emtricitabine, and tenofovir alafenamide to

15 Bictegravir, emtricitabine, and tenofovir alafenamide wa

16 The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide wa

17 due to adverse events (5 [2%] of 320 in the bictegravir group and 1 [<1%] 325 in the dolutegravir gr

18 eved in 286 (89%) of 320 participants in the bictegravir group and 302 (93%) of 325 in the dolutegrav

19 At week 24, 63 (96.9%) of 65 in the bictegravir group had HIV-1 RNA loads of less than 50 co

20 lated adverse events were less common in the bictegravir group than in the dolutegravir group (57 [18

21 enofovir alafenamide fixed-dose combination [bictegravir group] and 330 with dolutegravir plus emtric

22 Bictegravir is a novel, potent INSTI with a high in-vitr

23 pants (2:1) to receive oral once-daily 75 mg bictegravir or 50 mg dolutegravir with matching placebo

24 ported by 55 (85%) of 65 participants in the bictegravir plus emtricitabine and tenofovir alafenamide

25 INTERPRETATION: Bictegravir plus emtricitabine and tenofovir alafenamide

26 ing and giving study drug to 98 (65 received bictegravir plus emtricitabine and tenofovir alafenamide

27 One participant taking bictegravir plus emtricitabine and tenofovir alafenamide

28 320 participants who received the bictegravir regimen and 325 participants who received th

29 1.0, p=0.12), showing non-inferiority of the bictegravir regimen to the dolutegravir regimen.

30 t 48 weeks, virological suppression with the bictegravir regimen was achieved and was non-inferior to

31 se results, we did a phase 2 trial comparing bictegravir with dolutegravir.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。